Figures S1 through S19 from PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER<sup>+</sup> Breast Cancer
Anran Chen(Baylor College of Medicine), Matthew J. Ellis(University of California, Davis), Shou-Yun Yin, Meenakshi Anurag(Baylor College of Medicine), Carmine De Angelis(Baylor College of Medicine), Rachel Schiff(Baylor College of Medicine), Jacob B. Pilcher, Robert Papp, Xuxu Gou(Baylor College of Medicine), Donald W. Northfelt(Mayo Clinic in Arizona), Suzanne A.W. Fuqua(Baylor College of Medicine), Byung-Sun Kim(Korea Institute of Materials Science), Craig T. Vollert(University of Houston), Marc L. Hyer(AstraZeneca (United States)), Matthew P. Goetz, C Ma, Charles E. Foulds, Matthew V. Holt(Baylor College of Medicine), Jonathan T. Lei(Baylor College of Medicine), C. Gary Marshall, Susan G. Hilsenbeck (14952139), Aparna Mitra (19771222), Diana Fandiño
Cited by 0
Related Papers
A tutorial review of economic model predictive control methods
|Journal of Process Control|2014|711
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545